caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts diabetic heart disease. The molecule is a cholesterol translocation that impacts aging, non-alcoholic fatty liver disease, barth syndrome, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Tangier disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, cholesterol translocation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts diabetic heart disease, barth syndrome, and aging. | CCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts copd treatment. | CCC1CNCc2cccc(F)c2O1.Cl | [
"COPD treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti neoplastic and belongs to the anti body class of molecules, with the characteristic of being anti body drug conjugate. | CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(CN)Cc1ccc(N)cc1)OC)N(C)C(=O)CNC(=O)C(C(C)C)N(C)C | [
"anti neoplastic",
"anti body",
"anti body drug conjugate"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts aging and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Aging",
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the electroluminescent class of molecules. | c1ccc(-c2ccc(-c3cc(-c4ccccc4)cc(-c4nc(-c5ccccc5)nc(-c5ccc6c7ccccc7c7ccccc7c6c5)n4)c3)cc2)cc1 | [
"electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein kinase inhibitor. | N#Cc1c(-c2ccccc2-c2cc3ccccc3s2)[nH]c(=S)[nH]c1=O | [
"protein kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts insulin resistance, neurodegenerative disease, and diabetes mellitus. | CCC/C=C\CCCCCCCC/C=C/[C@@H](O)[C@H](CO)NC(=O)CCCC(O)/C=C/C=C/C/C=C/CCCCCCCC | [
"Insulin resistance",
"Neurodegenerative disease",
"Diabetes mellitus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a surfactant, a proton trap for oxidative phosphorylation, and a membrane stabilizer, and it impacts diabetic heart disease. The molecule is a energy source, cholesterol translocation, emulsifier that impacts tangier disease and barth syndrome. The molecule is a nutritional supplement and a food additiv... | CC(C)CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | [
"surfactant",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Membrane stabilizer",
"Tangier disease",
"Energy source",
"Cholesterol translocation",
"Emulsifier",
"Barth syndrome",
"Nutritional supplement",
"Smooth",
"Non-alcoholic fatty liver disease",
"food additive... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a flavoring agent, a nutrient, animal, cocoa, and castoreum. The molecule is mango, honey, and balsam; further, it is sweet, jasmine, and chocolate. | Cc1c(Cl)c(O)cc(O)c1C(=O)OC1CC2(C)C3CC(C)(C)CC3C=C(C=O)C12O | [
"Flavoring agent",
"nutrient",
"animal",
"cocoa",
"castoreum",
"mango",
"honey",
"balsam",
"sweet",
"jasmine",
"chocolate"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory disease treatment and belongs to the integrin antagonist class of molecules. | CCC(CC)Nc1cc(F)c(C(=O)NC(Cc2ccc(-c3c(C(F)(F)F)cc(C)n(C)c3=O)c3ncccc23)C(=O)O)c(F)c1 | [
"inflammatory disease treatment",
"integrin antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation, apoptosis that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts tangier disease, aging, non-alcoholic fatty liver disease, and diabetic heart disease. | CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pde1 inhibitor and belongs to the neurodegenerative treatment class of molecules, with the characteristic of being psychiatric treatment. | O=c1c2cnc(I)n2cc(Cc2ccc(Br)cc2)n1I | [
"psychiatric treatment",
"pde1 inhibitor",
"neurodegenerative treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage that impacts pancreatitis, metabolic syndrome, atherosclerosis, obesity, and cardiovascular disease. The molecule is a energy source and membrane stabilizer with an effect on cancer. The molecule is a inflammatory, a nutrient, and a fat storage, and it impacts thyroxine treatment. | CCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Pancreatitis",
"Metabolic syndrome",
"Energy storage",
"Atherosclerosis",
"Obesity",
"Cardiovascular disease",
"Energy source",
"Cancer",
"Membrane stabilizer",
"inflammatory",
"Thyroxine treatment",
"nutrient",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, energy source, membrane stabilizer that impacts metabolic syndrome, atherosclerosis, and obesity. The molecule is a inflammatory and nutrient, and it impacts cardiovascular disease. The molecule is a energy storage belonging to the thyroxine treatment class, known to affect cancer and imp... | CCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCC | [
"Fat storage",
"Energy source",
"Metabolic syndrome",
"Membrane stabilizer",
"Atherosclerosis",
"Obesity",
"inflammatory",
"nutrient",
"Cardiovascular disease",
"Cancer",
"Thyroxine treatment",
"Energy storage",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is photosensitive. | C=CC(=O)O.O=C1NC(=O)C2CCC=CC12 | [
"photosensitive"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts aging, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Tangier disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a osmolyte and a signalling molecule. | CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO | [
"osmolyte",
"signalling molecule"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts non-alcoholic fatty liver disease and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti viral. | CC(C)=CCCC(C)=CCO.COc1cc(C=CC(=O)O)ccc1O | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage and a nutrient that impacts metabolic syndrome, atherosclerosis, cardiovascular disease, and cancer. The molecule is a inflammatory and thyroxine treatment, and it impacts obesity. The molecule is a fat storage, a membrane stabilizer, and a energy source, and it impacts pancreatitis. | CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Metabolic syndrome",
"Energy storage",
"Atherosclerosis",
"nutrient",
"Cardiovascular disease",
"Cancer",
"Obesity",
"Thyroxine treatment",
"inflammatory",
"Fat storage",
"Membrane stabilizer",
"Energy source",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer and energy source, affecting cancer, and impacting cardiovascular disease, metabolic syndrome, and pancreatitis. The molecule is a fat storage that impacts both obesity and atherosclerosis. The molecule is a energy storage, a nutrient, a inflammatory, and thyroxine treatment. | CCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCC(C)C | [
"Cardiovascular disease",
"Membrane stabilizer",
"Metabolic syndrome",
"Cancer",
"Energy source",
"Pancreatitis",
"Obesity",
"Atherosclerosis",
"Fat storage",
"Energy storage",
"nutrient",
"inflammatory",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, nutrient, energy source that impacts pancreatitis, cancer, and thyroxine treatment. The molecule is a fat storage that impacts both obesity and cardiovascular disease. The molecule is a energy storage and a membrane stabilizer, impacting both metabolic syndrome and atherosclerosis. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Pancreatitis",
"inflammatory",
"Cancer",
"Thyroxine treatment",
"nutrient",
"Energy source",
"Obesity",
"Cardiovascular disease",
"Fat storage",
"Energy storage",
"Metabolic syndrome",
"Membrane stabilizer",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a food additive and a stabilizing mitochondrial structure, it impacts aging, and is smooth. The molecule is a stabilizing cytochrome oxidase, energy storage, energy source, emulsifier that impacts diabetic heart disease. The molecule is a cholesterol translocation and a membrane stabilizer, impacting bo... | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Smooth",
"Aging",
"food additive",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Energy storage",
"Energy source",
"Emulsifier",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Membrane stabilizer",
... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the muscarinic receptor antagonist class of molecules. | O=C(Nc1ccccc1-c1ccccc1)OC1CCN(CCCCc2ccc(CCNCC(O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)CC1 | [
"muscarinic receptor antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the luminescent class of molecules. | C=CC=CC(=CC)N(c1ccccc1NC)C(C)c1cc(-c2nc(C=CC=C)c(C)n2CC=CC=CC)cc(-c2nc3ccccc3n2C2=CCC=CC=CC2)c1 | [
"luminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti viral. | COCC1CC(c2nc3c(ccc4cc5c(cc43)OCc3cc(-c4cnc(C6(C(C)(C)C)CC(COC)CN6C(=O)O)[nH]4)ccc3-5)[nH]2)N(C(=O)OC(C)(C)C)C1 | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts aging and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Apoptosis",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts aging, diabetic heart disease, and barth syndrome. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Aging",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a apoptosis that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Cholesterol translocation",
"Aging",
"Apoptosis",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cancer treatment. | CNCCN(Cc1ncccc1C(F)(F)F)C(=O)CNc1cccc2c1CCN(C(=O)NC1CCCCC1)C2 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory disease treatment and a anti inflammatory, belonging to the psoriasis treatment class of molecules. | CCCCCCCCOc1cc(OCCCCCCCCOc2ccc(O)cc2)cc(C(=O)O)c1 | [
"inflammatory disease treatment",
"psoriasis treatment",
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein kinase inhibitor, a akt inhibitor, and cancer treatment. | COc1ccc(CC(N)C(=O)C(C)C)cc1 | [
"protein kinase inhibitor",
"cancer treatment",
"akt inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts diabetic heart disease and aging. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a treatment of disorder. | Cc1cc(OCc2ccccc2)c2n[nH]c(Br)c2n1 | [
"treatment of disorder"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure that impacts tangier disease and aging. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC | [
"Barth syndrome",
"Cholesterol translocation",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome and diabetic heart disease. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts aging, tangier disease, and non-alcoholic fatty liver disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Apoptosis",
"Aging",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis that impacts aging, barth syndrome, diabetic heart disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Apoptosis",
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and barth syndrome. | CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Cholesterol translocation",
"Diabetic heart disease",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and aging. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Cholesterol translocation",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Tangier disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cancer treatment. | O=C(O)Nc1cc(Oc2ccc([N+](=O)[O-])cn2)c(F)cc1F | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts barth syndrome and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Cholesterol translocation",
"Diabetic heart disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts atherosclerosis, breast cancer, cervical cancer, and ulcerative colitis. | CC/C=C\C[C@H](O)/C=C/C=C/C=C\C=C/[C@@H](O)[C@H](O)CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCc1oc(CCCCC)c(C)c1C)COP(=O)([O-])OCC[N+](C)(C)C | [
"Atherosclerosis",
"Breast cancer",
"nutrient",
"Cervical cancer",
"Ulcerative colitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and aging. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts barth syndrome and aging. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts diabetic heart disease, non-alcoholic fatty liver disease, and tangier disease. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease. The molecule is a apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts diabetic heart disease and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Barth syndrome",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects both cervical cancer and breast cancer, and also impacts atherosclerosis and ulcerative colitis. | CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)O/C=C\CCCCCCCCCCCCCC | [
"Atherosclerosis",
"Cervical cancer",
"nutrient",
"Breast cancer",
"Ulcerative colitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts tangier disease, non-alcoholic fatty liver disease, and aging. | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, inflammatory, nutrient that impacts atherosclerosis, metabolic syndrome, and cardiovascular disease. The molecule is a energy storage and thyroxine treatment, and it impacts obesity. The molecule is a membrane stabilizer and a fat storage, with effects on cancer and impacts on pancreati... | CCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Atherosclerosis",
"Energy source",
"inflammatory",
"Metabolic syndrome",
"nutrient",
"Cardiovascular disease",
"Thyroxine treatment",
"Obesity",
"Energy storage",
"Pancreatitis",
"Membrane stabilizer",
"Cancer",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation that impacts aging, tangier disease, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, green, sweet, balsamic, waxy. | Cc1ccc(S(=O)(=O)O)cc1.NCC(=O)OCc1ccccc1 | [
"nutrient",
"green",
"sweet",
"balsamic",
"waxy"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a protease inhibitor and a metalloprotease inhibitor. | CNCCOc1cccc(-c2ccc(C3CCN(S(=O)(=O)C(C)(C)C(=O)OC)CC3)cc2C)c1 | [
"protease inhibitor",
"metalloprotease inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both atherosclerosis and pancreatitis. The molecule is a fat storage that impacts cardiovascular disease, thyroxine treatment, and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\CCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"nutrient",
"Atherosclerosis",
"Pancreatitis",
"Cardiovascular disease",
"Thyroxine treatment",
"Metabolic syndrome",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease. The molecule is a apoptosis that impacts aging, tangier disease, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Aging",
"Apoptosis",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a flavoring agent, herbal, tomato, and lavender. The molecule is a nutrient, green, blueberry, and woody. | Cc1occc1SC(C(=O)CC(C)C)C(C)C | [
"herbal",
"Flavoring agent",
"tomato",
"lavender",
"nutrient",
"green",
"blueberry",
"woody"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the chemiluminescent class of molecules. | CCOC(=O)c1c(-n2ccnc2)nc(-c2ccccc2)c(N)c1C(=O)OCC | [
"chemiluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a surfactant, emulsifier, stabilizing mitochondrial structure, membrane stabilizer. The molecule is a stabilizing cytochrome oxidase, a cholesterol translocation, and a energy source, it impacts non-alcoholic fatty liver disease and is smooth. The molecule is a food additive and a nutritional supplement... | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"surfactant",
"Emulsifier",
"Stabilizing mitochondrial structure",
"Membrane stabilizer",
"Non-alcoholic fatty liver disease",
"Smooth",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Energy source",
"Tangier disease",
"Aging",
"food additive",
"Nutritional supplement",
"A... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti viral class of molecules. | CC(C)(C)Cc1cc2[nH]ccc(=O)c2s1 | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts barth syndrome, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Aging",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Barth syndrome",
"Diabetic heart disease",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a emulsifier, a surfactant, and a energy source. The molecule is a energy storage and a signalling molecule, impacting both chronic hepatitis and jaundice. It impacts depression, refsum's disease, and alzheimer's disease. The molecule is a membrane stabilizer that affects colorectal cancer by impacting ... | CC(CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C)C(=O)O | [
"Emulsifier",
"surfactant",
"Energy source",
"Chronic hepatitis",
"Energy storage",
"Jaundice",
"signalling molecule",
"Depression",
"Refsum's disease",
"Alzheimer's Disease",
"Cirrhosis",
"Membrane stabilizer",
"Chronic diarrhea",
"Colorectal cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1ccc(-c2oc3c(OC)cc(OC)c(OC)c3c(=O)c2OC)cc1 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cancer treatment. | CC1CN(c2nc(C3CC3)c3c(c2C#N)CC(C)(C)OC3)CCN1C(=O)c1ccco1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts aging. The molecule is a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, tangier disease, barth syndrome, and diabetic heart disease. | CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hbv inhibitor that impacts hepatitis b treatment. | O=C(Nc1cccc(C(F)(F)F)c1)c1cc(SNC2CCCCC2)ccc1F | [
"hepatitis b treatment",
"hbv inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti tumour and belongs to the anti tumor class of molecules, with the characteristic of being anti bacterial agent. The molecule is a anti biotic and belongs to the anti tumor agent class of molecules; it is anti bacterial and anti tumor activity. | CCOC(=O)c1cc2cc(NC(=O)c3ccc(C(=O)Nc4ccc5[nH]c(C(=O)OCC)cc5c4)o3)ccc2[nH]1 | [
"anti tumour",
"anti tumor",
"anti bacterial agent",
"anti bacterial",
"anti biotic",
"anti tumor activity",
"anti tumor agent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti viral class of molecules. | COC(=O)C(OC1CCC(n2cc(C)c(=O)[nH]c2=O)C1)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCCCCCCCCCCCCCCC(=O)OC(CC=C(C)C)/C(C)=C/COc1ccc(CCNC(=O)c2ccccc2)cc1 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hcv treatment and is anti viral. | S=C(NCCc1ccccc1)Nc1cccc(OCCCCCc2ccccc2)c1 | [
"anti viral",
"hcv treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti microbial agent, a anti bacterial, and a anti bacterial agent, it impacts cancer treatment and is anti microbial. | COc1cc2ncc(C)c(-c3ccc4c(c3)CN(C(=O)OC(C)(C)C)CC4)c2cc1OC | [
"anti microbial",
"anti microbial agent",
"anti bacterial",
"anti bacterial agent",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy source, waste product, nutrient, energy storage. | COc1ccccc1C(=O)OC1C(O)C(C)OC(Oc2cc(O)c3c(=O)c(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4OC4OC(CO)C(O)C(O)C4O)c(-c4ccc(O)cc4)oc3c2)C1O | [
"Membrane stabilizer",
"Energy source",
"Waste product",
"nutrient",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source that impacts renal cell carcinoma, inflammatory bowel disease, and breast cancer. It impacts heart failure, celiac disease, diabetes mellitus type 2, and cardiovascular disease. | CCCCC=CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Energy source",
"Renal cell carcinoma",
"Inflammatory bowel disease",
"Breast cancer",
"Heart failure",
"Celiac disease",
"Diabetes mellitus type 2",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a platelet aggregation inhibitor. | COC(=O)CCC=CC1=CC2CC(OC3CCCCO3)C(C=O)C2C1 | [
"platelet aggregation inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both cardiovascular disease and pancreatitis. The molecule is a nutrient and thyroxine treatment, impacting both metabolic syndrome and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Cardiovascular disease",
"Fat storage",
"Pancreatitis",
"Thyroxine treatment",
"Metabolic syndrome",
"nutrient",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a prmt5 inhibitor that impacts cancer treatment. | CC(=O)N1CCN(c2cc(C(=O)NCC(O)C3Cc4ccc(O)cc4CN3C(=O)O)cc(NC3CCC3)n2)CC1 | [
"prmt5 inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti bacterial. | O=C(NO)c1cccc(-c2ccc(C#Cc3cccnc3)cc2)n1 | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, surfactant, energy source, emulsifier, membrane stabilizer, energy storage. | COC(=O)C(OC(=O)c1cc(O)c(O)c(O)c1)C(O)C(O)C(O)C(=O)O | [
"nutrient",
"surfactant",
"Energy source",
"Emulsifier",
"Membrane stabilizer",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a liquid crystal. | CCCCCC1CCC(C(=O)Oc2ccc(C(=O)O)c(Cl)c2)CC1 | [
"liquid crystal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts diabetic heart disease and barth syndrome. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Diabetic heart disease",
"Apoptosis",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and smooth, impacting both diabetic heart disease and barth syndrome. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation, nutritional supplement that impacts aging. The molecule is a membrane stabilizer and a energy source, ... | CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Smooth",
"Diabetic heart disease",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Nutritional supplement",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Membrane stabilizer",
"En... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, alzheimer's disease, non-alcoholic fatty liver disease, and parkinson's disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](CO/C=C\CCCCCCCCCCCCCCCC)COP(=O)(O)OCCN | [
"Diabetes mellitus type 2",
"nutrient",
"Alzheimer's Disease",
"Non-alcoholic fatty liver disease",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both erythema and edema. | CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc1ccc2ccc(=O)oc2c1 | [
"nutrient",
"Erythema",
"Edema"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts tangier disease and diabetic heart disease. The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, aging, and barth syndrome. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Tangier disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ferroelectric and belongs to the liquid crystal class of molecules. | C=CC(=O)OCCCCCCCCCCCCOC1(CC(C)CC)C=CC(c2ccccc2)=CC1 | [
"liquid crystal",
"ferroelectric"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti apoptotic. | O=[N+]([O-])c1cc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)ccc1NC(CCN1CCC1)CSc1ccccc1 | [
"anti apoptotic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and a inflammatory that impacts atherosclerosis, obesity, metabolic syndrome, and cardiovascular disease. The molecule is a nutrient that impacts both thyroxine treatment and pancreatitis. The molecule is a energy storage, membrane stabilizer, energy source with an effect on cancer. | CCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCC | [
"Atherosclerosis",
"Fat storage",
"Obesity",
"Metabolic syndrome",
"inflammatory",
"Cardiovascular disease",
"nutrient",
"Thyroxine treatment",
"Pancreatitis",
"Energy storage",
"Membrane stabilizer",
"Cancer",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts diabetic heart disease, barth syndrome, and tangier disease. The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts aging and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anesthetic. | COc1ccc2c(c1)oc(=O)c1c3ccc(O)cc3oc21 | [
"anesthetic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts stomach cancer, alzheimer's disease, parkinson's disease, and cardiovascular disease. It has an effect on colorectal cancer, and impacts breast cancer, seizure, and diabetes mellitus. | CCCCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Stomach cancer",
"Alzheimer's Disease",
"Parkinson's disease",
"Cardiovascular disease",
"Colorectal cancer",
"Breast cancer",
"Seizure",
"Diabetes mellitus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cardiovascular disease, alzheimer's disease, diabetes mellitus, and seizure. It influences both stomach cancer and colorectal cancer, as well as affecting parkinson's disease and breast cancer. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C=C\[C@H](O)C/C=C\CCCCC)COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O | [
"Cardiovascular disease",
"Alzheimer's Disease",
"Diabetes mellitus",
"Seizure",
"Parkinson's disease",
"Stomach cancer",
"Breast cancer",
"Colorectal cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a surfactant and a membrane stabilizer, impacting both barth syndrome and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease. Th... | CCC(C)CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"surfactant",
"Membrane stabilizer",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Energy source",
"Smooth",
"N... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proteasome inhibitor. | O=C(O)C(O)(Cl)C(O)C(O)CO | [
"proteasome inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCC/C=C\C/C=C\C/C=C\CC1OC1CCCCC | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is sour, malt, peach, and ethereal. The molecule is a flavor that impacts hepatic encephalopathy and is chocolate, fatty, and aldehydic. | CCCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(=O)CCCCCCCCCCCCCCC | [
"sour",
"malt",
"peach",
"ethereal",
"chocolate",
"fatty",
"Hepatic encephalopathy",
"flavor",
"aldehydic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both atherosclerosis and metabolic syndrome. The molecule is a thyroxine treatment and a fat storage, impacting both pancreatitis and cardiovascular disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"Atherosclerosis",
"Metabolic syndrome",
"nutrient",
"Pancreatitis",
"Thyroxine treatment",
"Cardiovascular disease",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, diabetes mellitus type 2, parkinson's disease, and non-alcoholic fatty liver disease. | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCCC | [
"nutrient",
"Alzheimer's Disease",
"Diabetes mellitus type 2",
"Parkinson's disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, thyroxine treatment, membrane stabilizer, energy source, energy storage with an effect on cancer. The molecule is a inflammatory that impacts both obesity and atherosclerosis. The molecule is a nutrient that impacts pancreatitis, cardiovascular disease, and metabolic syndrome. | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCC | [
"Cancer",
"Fat storage",
"Thyroxine treatment",
"Membrane stabilizer",
"Energy source",
"Energy storage",
"Obesity",
"Atherosclerosis",
"inflammatory",
"Pancreatitis",
"Cardiovascular disease",
"nutrient",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts tangier disease, diabetic heart disease, barth syndrome, and aging. The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Barth syndrome",
"Aging",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts aging, tangier disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pain treatment. | COc1cccc(Nc2ncnc3c2CCN(c2cc(C(F)(F)F)ccn2)C3)c1 | [
"pain treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.